Sun Pharmaceutical Industries’ subsidiary has been granted the US Food and Drug Administration (USFDA) final approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta, Duloxetine Delayed-Release Capsules USP, 20 mg, 30 mg and 60 mg. Duloxetine Delayed-Release Capsules USP, 20 mg, 30 mg and 60 mg are therapeutic equivalents of Eli Lilly & Company’s Cymbalta Delayed-Release Capsules.
04:25
Unknown
Posted in:
0 comments:
Post a Comment